News Aptorum Group Limited

Equities

APM

KYG6096M1226

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
5.56 ^USD	+1.09%		-23.31%	+127.07%

Mar. 06	Top Midday Gainers	MT
Mar. 06	YOOV Group Holding Limited entered into a entered into an Agreement and Plan of Merger to acquire Aptorum Group Limited for $250 million in a reverse merger transaction.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Midday Gainers	Mar. 06	MT
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business	Mar. 06	BU
YOOV Group Holding Limited entered into a entered into an Agreement and Plan of Merger to acquire Aptorum Group Limited for $250 million in a reverse merger transaction.	Mar. 05	CI
Top Premarket Decliners	Jan. 29	MT
Aptorum Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	Dec. 22	CI
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023	Dec. 22	BU
Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders	Dec. 21	BU
Aptorum Group Limited Announces Chief Executive Changes	Nov. 30	CI
Aptorum Group Limited Announces Management Changes	Nov. 30	CI
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023	Nov. 16	BU
Aptorum : Securities Purchase Agreement - Form 6-K	23-09-11	PU
Aptorum Group Limited announced that it has received $3 million in funding from Jurchen Investment Corporation	23-09-10	CI
Top Premarket Decliners	23-08-28	MT
Aptorum Group Obtains Nasdaq Authorization to Transfer Listing to Nasdaq Capital Market	23-08-10	MT
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets	23-08-10	BU
Top Premarket Gainers	23-07-18	MT
Aptorum Group Limited Announces Resignation of Thomas Lee as Head of Research and Development	23-06-30	CI
Aptorum Group Limited announced that it has received $3 million in funding	23-06-27	CI
Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma	23-06-22	BU
Aptorum Group Limited Provides Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma	23-06-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Aptorum Group Limited

Equities

APM

KYG6096M1226

Summary

Filters